ES2054696T3 - Agente viral de la hepatitis nanb, antigen y reactivo inmunologico. - Google Patents

Agente viral de la hepatitis nanb, antigen y reactivo inmunologico.

Info

Publication number
ES2054696T3
ES2054696T3 ES87402519T ES87402519T ES2054696T3 ES 2054696 T3 ES2054696 T3 ES 2054696T3 ES 87402519 T ES87402519 T ES 87402519T ES 87402519 T ES87402519 T ES 87402519T ES 2054696 T3 ES2054696 T3 ES 2054696T3
Authority
ES
Spain
Prior art keywords
antigen
viral
nanb
viral agent
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87402519T
Other languages
English (en)
Inventor
Jacques Pillot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR8615625A external-priority patent/FR2606515B1/fr
Priority claimed from FR8701738A external-priority patent/FR2609807B2/fr
Application filed by Institut Pasteur filed Critical Institut Pasteur
Application granted granted Critical
Publication of ES2054696T3 publication Critical patent/ES2054696T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

NUEVO AGENTE VIRUL PURIFICADO, IMPLICADO EN LA HEPATITIS VIRAL NO - A NO B, EPIDEMIA, ESPORADICA O POST - TRANSFUSIONAL, DEFINIDO EL PERFIL DE REPARTICION DE SU ACTIVIDAD ANTIGENA, QUE COMPORT6A AL MENOS UNA BANDA DE DENSIDAD 1,28 - 1,32 G/CM3 Y/O AL MENOS UNA BANDA DE DENSIDAD DE 1,17 - 1,19 G/CM3, Y EL ANTIGENO ASOCIADO A ESTE AGENTE VIRAL. PROCEDIMIENTO PARA AISLAR DICHO AGENTE VIRAL Y EL ANTIGENO QUE LE ES ASOCIADO, UTILIZACION DEL AGENTE VIRAL MIENTRAS SE REACTIVA EL DIAGNOSTICO. PROCEDIMIENTO DE DETECCION DEL ANTIGENO NO - A NO - B PRESENTE EN LAS HECES DE LOS PACIENTES ATENDIDOS DE HEPATITS VIRAL NO - A NO - B. REACTIVO INMUNOLOGICO PARA LA DETECCION DE LA HEPATITIS VIRAL NANB, EPIDEMICA, ESPORADICA O POST - TRANSFERENCIAL Y PROCESO DE AISLAMIENTO DE ANTICUERPOS ANTI - NANB APTOS PARA SER UTILIZADOS MIENTRAS LOS REACTIVOS INMUNOLOGICOS, APLICACION DE DICHOS ANTICUERPOS ANTI - NANB EN EL DIAGNOSTICO DE LA HEPATITIS VIRAL NANB EPIDEMICA, ESPORADICA O POST TRANSFERENCIAL Y EN EL TRANSCURSO DE LOS AGENTES TERAPEUTICOS.
ES87402519T 1986-11-07 1987-11-06 Agente viral de la hepatitis nanb, antigen y reactivo inmunologico. Expired - Lifetime ES2054696T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8615625A FR2606515B1 (fr) 1986-11-07 1986-11-07 Procede pour l'isolement d'un nouvel agent viral et de l'antigene qui lui est associe, agent viral et antigene obtenus par ce procede et procede de detection dudit antigene a l'aide d'un reactif immunologique approprie
FR8701738A FR2609807B2 (fr) 1987-02-11 1987-02-11 Reactifs immunologiques pour la detection de l'hepatite virale nanb, leurs procedes de preparation et leurs applications dans des procedes de detection de l'hepatite virale nanb et en tant qu'agents therapeutiques

Publications (1)

Publication Number Publication Date
ES2054696T3 true ES2054696T3 (es) 1994-08-16

Family

ID=26225574

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87402519T Expired - Lifetime ES2054696T3 (es) 1986-11-07 1987-11-06 Agente viral de la hepatitis nanb, antigen y reactivo inmunologico.

Country Status (7)

Country Link
EP (1) EP0277437B1 (es)
JP (1) JP2602517B2 (es)
AU (1) AU611402B2 (es)
DE (1) DE3784484T2 (es)
ES (1) ES2054696T3 (es)
NZ (1) NZ222465A (es)
WO (1) WO1988003410A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712088A (en) * 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
GB2212511B (en) * 1987-11-18 1992-01-22 Chiron Corp Hepatitis c virus
US6861212B1 (en) 1987-11-18 2005-03-01 Chiron Corporation NANBV diagnostics and vaccines
US5698390A (en) * 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
US5714596A (en) * 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
BR8807310A (pt) * 1987-11-18 1990-03-13 Chiron Corp Polinucleotidio,polinucleotidio recombinante,vetor recombinante,celula hospedeira,sistema de expressao recombinante,celula transformada,polipeptidio,hcv,preparacao de polipeptidio,polipeptidio de hcv,polipeptidio purificado,polipeptidio recombinante,polipeptidio de fusao,anticorpo monoclonal,preparacao purificada de anticorpos policlonais,particula,sonda de polinucleotidio,kit anticorpo para epetopo de hcv,metodo para producao de polipeptidio,metodo para deteccao de acidos nucleicos de hcv,imunoensaio para detectar antigeno de hcv,imunoensaio para detectar anticorpos dirigidos contra antigeno de hcv,vacina para tratamento de infeccao de hcv,celula,celula infectada com hcv,metodo para producao de anticorpos para hcv e metodo para isolar cdna derivado do genoma de um agente infeccioso nao identificado
US6171782B1 (en) 1987-11-18 2001-01-09 Chiron Corporation Antibody compositions to HCV and uses thereof
US5824649A (en) * 1988-06-17 1998-10-20 Genelabs Technologies, Inc. DNA sequences of enterically transmitted non-A/non-B hepatitis viral agent and characteristic epitopes thereof
US5789559A (en) * 1988-06-17 1998-08-04 Genelabs Technologies, Inc. DNA sequences of enterically transmitted non-A/non-B hepatitis viral agent
DE3837616A1 (de) * 1988-11-05 1990-05-10 Behringwerke Ag Einschritt-immuntest zur bestimmung von antigen-spezifischen antikoerpern aller immunglobulin-klassen und dazu geeignetes mittel
US6027729A (en) * 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
US7166287B1 (en) 1989-12-18 2007-01-23 Glaxo Wellcome Inc. Viral agent
CA2032381C (en) * 1989-12-18 2006-02-21 Peter E. Highfield Viral agent
EP0447984A1 (en) * 1990-03-20 1991-09-25 Abbott Laboratories Hyperimmune globulin against hepatitis C virus and method for making same
KR100241221B1 (ko) * 1991-08-26 2000-03-02 에드워드 콜린스 제임스 돼지 불임 및 호흡기계 중후백신 및 그의 진단법
US6982160B2 (en) 1991-08-26 2006-01-03 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions that include SIRS virus
US6080570A (en) * 1991-08-26 2000-06-27 Boehringer Ingelheim Vetmedica, Inc. Method of producing a vaccine for Swine Infertility and Respiratory Syndrome
US5846805A (en) 1991-08-26 1998-12-08 Boehringer Ingelheim Animal Health, Inc. Culture of swine infertility and respiratory syndrome virus in simian cells
AU2696792A (en) * 1991-09-16 1993-04-27 David A Benfield Vaccine for mystery swine disease and method for diagnosis thereof
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
CA2366072C (en) 1999-03-08 2007-07-10 Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. Prrsv vaccines
ES2348159T3 (es) 1999-04-22 2010-11-30 United States Department Of Agriculture Vacuna contra el sindrome respiratorio y reproductivo porcino basada en el aislado ja-142.
TW200604526A (en) 2004-06-18 2006-02-01 Unviersity Of Minnesota Identifying virally infected and vaccinated organisms
US7632636B2 (en) 2004-09-21 2009-12-15 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome isolates and methods of use
PT2369001T (pt) 2005-06-24 2016-10-25 Univ Minnesota Vírus srrp, clones infecciosos, os seus mutantes e processos de utilização
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
CA2827337C (en) 2011-02-17 2019-07-09 Boehringer Ingelheim Vetmedica Gmbh Commercial scale process for production of prrsv
ES2692809T3 (es) 2011-02-17 2018-12-05 Boehringer Ingelheim Vetmedica Gmbh Nueva cepa del PRRSV europea
US9187731B2 (en) 2011-07-29 2015-11-17 Boehringer Ingelheim Vetmedica Gmbh PRRS virus inducing type I interferon in susceptible cells
US9315781B2 (en) 2011-07-29 2016-04-19 Boehringer Ingelheim Vetmedica Gmbh Infectious CDNA clone of european PRRS virus and uses thereof
US9579373B2 (en) 2013-03-15 2017-02-28 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
CN105829528B (zh) 2013-12-20 2019-10-22 勃林格殷格翰动物保健有限公司 PRRS病毒变体、欧洲PRRS病毒cDNA克隆及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356164A (en) * 1979-05-21 1982-10-26 Govt. of the U.S., as represented by the Secretary, Dept. of Health & Human Services Detection of non-A, non-B hepatitis associated antigen
AU540153B2 (en) * 1979-05-21 1984-11-01 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Detection of non-a, non-b hepatitis associated antigen
WO1982002774A1 (en) * 1981-02-11 1982-08-19 Baxter Travenol Lab Non-a,non-b hepatitis virus
US4542016A (en) * 1981-03-27 1985-09-17 Institut Merieux Non-a non-b hepatitis surface antigen useful for the preparation of vaccines and methods of use
FR2502154A1 (fr) * 1981-03-30 1982-09-24 Trepo Christian Procede de preparation d'antigenes de l'hepatite virale nanb, et application a la realisation d'un reactif permettant le diagnostic et le pronostic des infections provoquees par les virus des hepatites virales
JPS57198867A (en) * 1981-06-02 1982-12-06 Eisai Co Ltd Non-a, non-b hepatitis related antigen and diagnostic therefor
JPS58753A (ja) * 1981-06-25 1983-01-05 Eisai Co Ltd 非ａ非ｂ型肝炎関連抗体および検出試薬
JPS58183629A (ja) * 1982-04-21 1983-10-26 Eisai Co Ltd 非ａ非ｂ型肝炎関連モノクロナ−ル抗体および診断薬
DE3377401D1 (de) * 1982-05-05 1988-08-25 Univ Louisiana State Non-a, non-b hepatitis antigen
FR2597606B1 (fr) * 1986-04-16 1989-10-06 Pasteur Institut Nouveau reactif pour la detection d'hepatites virales non a non b et procede de diagnostic de telles hepatites par voie immunoenzymatique

Also Published As

Publication number Publication date
EP0277437B1 (fr) 1993-03-03
DE3784484T2 (de) 1993-07-01
DE3784484D1 (de) 1993-04-08
JPH01501205A (ja) 1989-04-27
NZ222465A (en) 1992-11-25
AU8273487A (en) 1988-06-01
AU611402B2 (en) 1991-06-13
JP2602517B2 (ja) 1997-04-23
EP0277437A1 (fr) 1988-08-10
WO1988003410A1 (fr) 1988-05-19

Similar Documents

Publication Publication Date Title
ES2130121T3 (es) Antigeno intra-acrosomico de esperma humano para uso en una vacuna anticonceptiva.
DK614987D0 (da) Syntetiske htlv-iii peptider, praeparater og anvendelser deraf
NO923839L (no) Kombinasjoner av hepatitt c-virus(hcv)-antigener for anvendelse i immunoanalyser for anti-hcv-antistoffer
DE69327307D1 (de) Herstellung von antigenen und impfstoffen vom mysterie-disease-virus, antigene und erworbene impfstoffe zur verhinderung dieser krankheit
DK0610250T3 (da) Vaccine med porcint reproduktivt respiratorisk syndrom og diagnose heraf
ES2110411T3 (es) Metodos para cultivar el virus de la hepatitis c (hcv) en lineas celulares de linfocitos b o t.
ATE17320T1 (de) Impfstoff, therapie gegen nicht-a nicht-b virale hepatitis und verfahren zur herstellung desselben.
BE852416A (fr) Procede de purification et d'isolation du virus de l'hepatite en vue de l'utiliser dans la preparation de vaccins
ES2139607T3 (es) Anticuerpos monoclonales contra las proteinas e2/ns1 supuestas vhc y procedimientos de utilizacion de estos anticuerpos.
DK388384D0 (da) Monoklone antistoffer med specifitet for membran-associerede antigene, deres fremstilling og anvendelse
ES2065863T3 (es) Analisis para la deteccion de virus de la hepatitis c.
FI873553A7 (fi) HIV-infektioiden hoitoon ja diagnostisointiin käyttökelpoisia monoklonaalisia vasta-aineita ja peptidejä
DE3784484D1 (de) Hepatitis nanb-viraler stoff, antigen und immunologisches reagenz.
ES2050114T3 (es) Anticuerpos monoclonales humanos para el virus asociado a la linfoadenopatia.
KR890700662A (ko) 바이러스 항원과 그의 제조방법 및 진단과 치료를 목적으로 하는 사용방법
DK372780A (da) Fremgangsmaade til propagering af humant hepatitis a virus
ES2100893T3 (es) Procedimiento de preparacion de una vacuna o de un agente toxico.
SE7707889L (sv) Haptoglobinpreparat
ES2118129T3 (es) Anticuerpos monoclonales contra las regiones de cubierta putativas del virus vhc y procedimientos de utilizacion de estos.
ES2074983T3 (es) Procedimieto para el aislamiento de proteinas de membranas basales a partir de tejidos humanos y animales.
FI883723A7 (fi) Ihmisen monoklonaaliset vasta-aineet ja niitä vaikuttavana aineosana s isältävät terapeuttiset aineet infektiotauteja vastaan
Olaleye et al. Igbo-Ora virus (an alphavirus isolated in Nigeria): a serological survey for haemagglutination inhibiting antibody in humans and domestic animals
ES2126598T3 (es) Anticuerpos monoclonales que se fijan sobre las proteinas ns5 supuestas del virus de la hepatitis c, y procedimientos de utilizacion de estos anticuerpos.
Henle et al. Cross-reactions among γ-globulins of various species in indirect immunofluorescence
ES2013665A6 (es) Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 277437

Country of ref document: ES